162 related articles for article (PubMed ID: 37750290)
1. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
Zou P; Chen Z; He Q; Zhuo Y
Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
[TBL] [Abstract][Full Text] [Related]
2. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
[TBL] [Abstract][Full Text] [Related]
3. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV alleviates neuronal ferroptosis in ischemic stroke by regulating fat mass and obesity-associated-N6-methyladenosine-acyl-CoA synthetase long-chain family member 4 axis.
Jin Z; Gao W; Guo F; Liao S; Hu M; Yu T; Yu S; Shi Q
J Neurochem; 2023 Jul; 166(2):328-345. PubMed ID: 37300304
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
10. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
Yang Y; Liu T; Hu C; Xia H; Liu W; Chen J; Wu S; Jiang Y; Xu Y; Liu W; Zhao L
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649848
[TBL] [Abstract][Full Text] [Related]
12. EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p/ACSL4 axis.
Yu Q; Zhang N; Gan X; Chen L; Wang R; Liang R; Jian J
Phytomedicine; 2023 Oct; 119():154999. PubMed ID: 37597361
[TBL] [Abstract][Full Text] [Related]
13. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
14. Maresin-1 inhibits high glucose induced ferroptosis in ARPE-19 cells by activating the Nrf2/HO-1/GPX4 pathway.
Li Y; Liu J; Ma X; Bai X
BMC Ophthalmol; 2023 Sep; 23(1):368. PubMed ID: 37674121
[TBL] [Abstract][Full Text] [Related]
15. QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1
Cao H; Wu X; Gao R; Chen L; Feng Y; Wang D
J Cancer; 2023; 14(12):2236-2245. PubMed ID: 37576395
[TBL] [Abstract][Full Text] [Related]
16. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
[TBL] [Abstract][Full Text] [Related]
17. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
19. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]